These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Mechanistic aspects of the formation of α-dystroglycan and therapeutic research for the treatment of α-dystroglycanopathy: A review. Taniguchi-Ikeda M; Morioka I; Iijima K; Toda T Mol Aspects Med; 2016 Oct; 51():115-24. PubMed ID: 27421908 [TBL] [Abstract][Full Text] [Related]
44. Abnormal glycosylation of dystroglycan in human genetic disease. Hewitt JE Biochim Biophys Acta; 2009 Sep; 1792(9):853-61. PubMed ID: 19539754 [TBL] [Abstract][Full Text] [Related]
45. Congenital muscular dystrophies and the extracellular matrix. Schessl J; Zou Y; Bönnemann CG Semin Pediatr Neurol; 2006 Jun; 13(2):80-9. PubMed ID: 17027857 [TBL] [Abstract][Full Text] [Related]
50. Autologous intramuscular transplantation of engineered satellite cells induces exosome-mediated systemic expression of Fukutin-related protein and rescues disease phenotype in a murine model of limb-girdle muscular dystrophy type 2I. Frattini P; Villa C; De Santis F; Meregalli M; Belicchi M; Erratico S; Bella P; Raimondi MT; Lu Q; Torrente Y Hum Mol Genet; 2017 Oct; 26(19):3682-3698. PubMed ID: 28666318 [TBL] [Abstract][Full Text] [Related]
51. The genetic and molecular basis of muscular dystrophy: roles of cell-matrix linkage in the pathogenesis. Kanagawa M; Toda T J Hum Genet; 2006; 51(11):915-926. PubMed ID: 16969582 [TBL] [Abstract][Full Text] [Related]
52. Defect in glycosylation that causes muscular dystrophy. Endo T; Manya H Methods Enzymol; 2006; 417():137-52. PubMed ID: 17132503 [TBL] [Abstract][Full Text] [Related]
53. TRAPPC11-related muscular dystrophy with hypoglycosylation of alpha-dystroglycan in skeletal muscle and brain. Munot P; McCrea N; Torelli S; Manzur A; Sewry C; Chambers D; Feng L; Ala P; Zaharieva I; Ragge N; Roper H; Marton T; Cox P; Milev MP; Liang WC; Maruyama S; Nishino I; Sacher M; Phadke R; Muntoni F Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12771. PubMed ID: 34648194 [TBL] [Abstract][Full Text] [Related]
54. [Dystroglycan glycosylation and muscular dystrophy]. Kanagawa M Seikagaku; 2014 Aug; 86(4):452-63. PubMed ID: 25255627 [No Abstract] [Full Text] [Related]
55. LARGE expression in different types of muscular dystrophies other than dystroglycanopathy. Balci-Hayta B; Talim B; Kale G; Dincer P BMC Neurol; 2018 Dec; 18(1):207. PubMed ID: 30553274 [TBL] [Abstract][Full Text] [Related]
56. A new patient-derived iPSC model for dystroglycanopathies validates a compound that increases glycosylation of α-dystroglycan. Kim J; Lana B; Torelli S; Ryan D; Catapano F; Ala P; Luft C; Stevens E; Konstantinidis E; Louzada S; Fu B; Paredes-Redondo A; Chan AE; Yang F; Stemple DL; Liu P; Ketteler R; Selwood DL; Muntoni F; Lin YY EMBO Rep; 2019 Nov; 20(11):e47967. PubMed ID: 31566294 [TBL] [Abstract][Full Text] [Related]
57. Glycosylation with ribitol-phosphate in mammals: New insights into the O-mannosyl glycan. Manya H; Endo T Biochim Biophys Acta Gen Subj; 2017 Oct; 1861(10):2462-2472. PubMed ID: 28711406 [TBL] [Abstract][Full Text] [Related]
58. Limb-girdle muscular dystrophy type 2I is not rare in Taiwan. Liang WC; Hayashi YK; Ogawa M; Wang CH; Huang WT; Nishino I; Jong YJ Neuromuscul Disord; 2013 Aug; 23(8):675-81. PubMed ID: 23800702 [TBL] [Abstract][Full Text] [Related]
59. Increased levels of expression of dystroglycan may protect the heart. Brancaccio A Neuromuscul Disord; 2013 Nov; 23(11):867-70. PubMed ID: 23911074 [TBL] [Abstract][Full Text] [Related]
60. Fukutin gene mutations in steroid-responsive limb girdle muscular dystrophy. Godfrey C; Escolar D; Brockington M; Clement EM; Mein R; Jimenez-Mallebrera C; Torelli S; Feng L; Brown SC; Sewry CA; Rutherford M; Shapira Y; Abbs S; Muntoni F Ann Neurol; 2006 Nov; 60(5):603-610. PubMed ID: 17044012 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]